Devin Tucker1, Kanna Hayashi2, M-J Milloy2, Seonaid Nolan2, Huiru Dong1, Thomas Kerr2, Evan Wood3. 1. British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada. 2. British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada; Department of Medicine, University of British Columbia, 608-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada. 3. British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada; Department of Medicine, University of British Columbia, 608-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada. Electronic address: uhri-ew@cfenet.ubc.ca.
Abstract
BACKGROUND: Though known to have abuse potential, benzodiazepine medications remain widely prescribed. Furthermore, issues related to benzodiazepine use by people who inject drugs (PWID) remain to be fully characterized. We therefore sought to examine the prevalence of and risk factors associated with benzodiazepine use in a street-involved urban population. METHODS: Between May 1996 and November 2013, data were derived from two open prospective cohort studies in Vancouver, Canada, restricted to PWID. Multivariable logistic regression with generalized estimating equations (GEE) was used to determine factors independently associated with benzodiazepine use. RESULTS: Over the study period, 2806 individuals were recruited, including 949 (34%) women. Of these, 1080 (38.5%) participants reported benzodiazepine use at least once during the study period. In the multivariable analysis, Caucasian ethnicity, ≥ daily heroin injection, ≥ daily cocaine injection, non-fatal overdose, incarceration, syringe sharing, and unsafe sex were all independently associated with benzodiazepine use. Conversely, older age, homelessness, and ≥ daily crack smoking were negatively associated with benzodiazepine use. CONCLUSIONS: Use of benzodiazepines was common in this urban setting and was associated with several markers of addiction severity and significant health and social vulnerabilities including syringe sharing and unsafe sex. These findings underscore the need to promote treatment for benzodiazepine use, safer benzodiazepine prescribing, including greater recognition of the limited indications for evidence-based use of this medication class.
BACKGROUND: Though known to have abuse potential, benzodiazepine medications remain widely prescribed. Furthermore, issues related to benzodiazepine use by people who inject drugs (PWID) remain to be fully characterized. We therefore sought to examine the prevalence of and risk factors associated with benzodiazepine use in a street-involved urban population. METHODS: Between May 1996 and November 2013, data were derived from two open prospective cohort studies in Vancouver, Canada, restricted to PWID. Multivariable logistic regression with generalized estimating equations (GEE) was used to determine factors independently associated with benzodiazepine use. RESULTS: Over the study period, 2806 individuals were recruited, including 949 (34%) women. Of these, 1080 (38.5%) participants reported benzodiazepine use at least once during the study period. In the multivariable analysis, Caucasian ethnicity, ≥ daily heroin injection, ≥ daily cocaine injection, non-fatal overdose, incarceration, syringe sharing, and unsafe sex were all independently associated with benzodiazepine use. Conversely, older age, homelessness, and ≥ daily crack smoking were negatively associated with benzodiazepine use. CONCLUSIONS: Use of benzodiazepines was common in this urban setting and was associated with several markers of addiction severity and significant health and social vulnerabilities including syringe sharing and unsafe sex. These findings underscore the need to promote treatment for benzodiazepine use, safer benzodiazepine prescribing, including greater recognition of the limited indications for evidence-based use of this medication class.
Authors: Pirkko Kriikku; Hannes Hurme; Lars Wilhelm; Janne Rintatalo; Jukka Hurme; Jan Kramer; Ilkka Ojanperä Journal: Ther Drug Monit Date: 2015-06 Impact factor: 3.681
Authors: Liza M Reifler; Danna Droz; J Elise Bailey; Sidney H Schnoll; Reginald Fant; Richard C Dart; Becki Bucher Bartelson Journal: Pain Med Date: 2012-02-02 Impact factor: 3.750
Authors: S A Strathdee; A Palepu; P G Cornelisse; B Yip; M V O'Shaughnessy; J S Montaner; M T Schechter; R S Hogg Journal: JAMA Date: 1998-08-12 Impact factor: 56.272
Authors: Pedro Mateu-Gelabert; Lauren Jessell; Elizabeth Goodbody; Dongah Kim; Krista Gile; Jennifer Teubl; Cassandra Syckes; Kelly Ruggles; Jeffrey Lazar; Sam Friedman; Honoria Guarino Journal: Int J Drug Policy Date: 2017-05-31
Authors: Benjamin A Bouvier; Katherine M Waye; Beth Elston; Scott E Hadland; Traci C Green; Brandon D L Marshall Journal: Drug Alcohol Depend Date: 2017-12-07 Impact factor: 4.492
Authors: Lorenzo Zamboni; Igor Portoghese; Alessio Congiu; Thomas Zandonai; Rebecca Casari; Francesca Fusina; Anna Bertoldi; Fabio Lugoboni Journal: Front Psychiatry Date: 2022-01-25 Impact factor: 4.157